Eli Lilly and Company
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Eli Lilly and Company's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $82 of operating cash. Lower than 89% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $44 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $35 tied up three years earlier. More money tied up than 86% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$82Over the last 3 years, every $100 of reported profit came with $82 of operating cash.
Lower than 89% of Healthcare companies in United States.
Self-Funding Ratio
1.1×Over the last 3 years its own operating cash covered its investment spending (capex) 1.1 times.
Higher than 69% of Healthcare companies in United States.
Cash Locked Ratio
$44For every $100 of sales, $44 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $35 tied up three years earlier.
More money tied up than 86% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$39Sales grew 128% in 3 years; of every extra $100 of sales, $39 became extra profit.
Higher than 63% of Healthcare companies in United States.
Asset Productivity Ratio
+128% / +127%In 3 years sales changed by +128% while total assets changed by +127%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
10.3×Debt due within a year is covered 10.3 times by its yearly operating cash.
Higher than 85% of Healthcare companies in United States.
Cash Cushion Ratio
−3%Debt, after subtracting cash, equals 3% of its market value (net debt).
Lower than 72% of Healthcare companies in United States.
Tangible Assets Ratio
89%Of every $100 the company owns, $89 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 60% of Healthcare companies in United States.
Tangible Net Worth Ratio
53%Of every $100 of net worth, $53 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 51% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Eli Lilly and Company owes $0.76 for every $1 it owns. Net profit rose 95% in the year to Dec 2025, and grew 49% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
43.9Investors pay $43.9 for every $1 of Eli Lilly and Company's yearly profit, higher than 76% of Healthcare companies in United States.
P/B ratio
34.39The share price is 34.39 times Eli Lilly and Company's book value per share, higher than 97% of Healthcare companies in United States.
Market cap
$1,165.2 BThe total market value of all of Eli Lilly and Company's shares at today's price (share price × number of shares), larger than almost all Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$33.9 BWhat Eli Lilly and Company would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$37.99Net worth divided by the number of shares. The share price of $1,307 is 34.4 times this, which is the P/B above.
Return on equity (ROE)
102.3%Eli Lilly and Company earned 102.3% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
Owes vs Owns
0.76×Eli Lilly and Company owes $0.76 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Dividend yield
0.54%Eli Lilly and Company pays 0.54% of its share price as dividends a year, lower than 78% of dividend-paying Healthcare companies in United States.
Revenue growth
+45%Revenue rose 45% in the year to Dec 2025, and grew 32% a year on average over 3 years.
Profit growth
+95%Net profit rose 95% in the year to Dec 2025, and grew 49% a year on average over 3 years.
Profit margin
31.7%Eli Lilly and Company keeps $32 of every $100 of revenue as net profit.
Cash quality
0.8×Cash from Eli Lilly and Company's business was 0.8× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Cash vs debt
Net debtEli Lilly and Company had $35.2 B more debt than cash (net debt) at Dec 2025.
Questions
What is Eli Lilly and Company's P/E ratio?
Investors pay $43.9 for every $1 of Eli Lilly and Company's yearly profit, higher than 76% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Eli Lilly and Company: $1,165.2 B ÷ $33.9 B (30 Jun 2026) = 34.4.
What is Eli Lilly and Company's return on equity?
Eli Lilly and Company earned 102.3% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
How much does Eli Lilly and Company owe compared with what it owns?
Eli Lilly and Company owes $0.76 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Does Eli Lilly and Company pay a dividend?
Yes. Eli Lilly and Company pays 0.54% of its share price as dividends a year, lower than 78% of dividend-paying Healthcare companies in United States.
Is Eli Lilly and Company's revenue growing?
Revenue rose 45% in the year to Dec 2025, and grew 32% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.